GlassScriptPhysician profile
Elinore M Downing
NPI 1699217877
$8,198.15
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,827 · 2022: $2,276 · 2023: $2,220 · 2024: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,094.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,113.09 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $921.22 | 2021-2024 | Jardiance, Synjardy |
| Abbvie INC. | $872.95 | 2021-2024 | |
| Novo Nordisk INC | $717.23 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $682.35 | 2021-2023 | |
| Lilly USA, LLC | $568.40 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $448.22 | 2021-2024 | Repatha, Otezla |
| Amneal Pharmaceuticals LLC | $271.18 | 2021-2023 | Unithroid |
| Janssen Pharmaceuticals, INC | $254.32 | 2021-2023 | Xarelto |
| Pfizer INC. | $212.03 | 2023-2024 | |
| Glaxosmithkline, LLC. | $187.70 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceuticals, INC. | $186.79 | 2021 | |
| Antares Pharma, INC. | $175.04 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.42 | 2021-2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $133.15 | 2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elinore Downing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.